Advertisement
Advertisement
U.S. markets open in 6 hours 39 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Emmaus Life Sciences, Inc. (EMMA)

Other OTC - Other OTC Delayed Price. Currency in USD
0.3800-0.0200 (-5.00%)
At close: 03:49PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4000
Open0.3700
Bid0.0000 x 1800
Ask0.0000 x 1300
Day's Range0.3450 - 0.3800
52 Week Range0.0710 - 4.0000
Volume7,315
Avg. Volume39,727
Market Cap18.832M
Beta (5Y Monthly)1.77
PE Ratio (TTM)N/A
EPS (TTM)-0.1840
Earnings DateNov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for EMMA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • EMMAUS LIFE SCIENCES INC NEW
    Daily – Vickers Top Insider Picks for 03/21/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    8 months agoArgus Research
View more
  • PR Newswire

    Emmaus Life Sciences Receives Endari® Marketing Authorization from the Qatar Ministry of Public Health

    Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease treatment, announced today that it has been issued a Registration Certificate from the Registration Committee for Pharmaceutical Companies & their Products of the Qatar Ministry of Public Health granting marketing authorization for the commercial distribution and sale of Endari® in the country. The company also announced that it received its first major purchase order from its distributor in the Kingdom of Saudi Arabia, wh

  • Zacks Small Cap Research

    EMMA: Growing Revenue and Treating Sickle Cell

    By Brad Sorensen, CFA OTC:EMMA READ THE FULL EMMA RESEARCH REPORT EMMA (OTC:EMMA) is a commercial stage biopharma company bringing relief to sickle cell sufferers and looking to expand their reach. Emmaus Life Sciences, Inc. is expanding the reach of Endari, its treatment for sickle cell disease, while also pursuing other treatments to add to its portfolio. The company reported 3Q 2022 earnings

  • PR Newswire

    /C O R R E C T I O N -- Emmaus Life Sciences, Inc./

    Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its results of operations and financial condition as of and for the three and nine months ended September30, 2022 and provided a business update.

Advertisement
Advertisement